ClinicalTrials.govpublic full text
An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
down syndrome regression disorder (dsrd), down syndrome (trisomy 21), neuroinflammatory / neuropsychiatric disorder, ublituximab, b-cell depletion, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 969067
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.